Core Insights - Traws Pharma is hosting a virtual investor event on March 31, 2025, to discuss its investigational oral small molecule product candidates targeting respiratory viral diseases [1][2] - The event will feature key management personnel, including Robert R. Redfield, MD, and C. David Pauza, PhD, who will present data and engage in a Q&A session [2] Traws Pharma Overview - Traws Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapies for respiratory viral diseases [9][10] - The company is advancing investigational antiviral agents with potent activity against resistant virus strains, aiming for safe and simple dosing regimens [9] Product Candidates Tivoxavir Marboxil - Tivoxavir marboxil (TXM) is an investigational oral small molecule designed as a single-dose treatment for bird flu and seasonal influenza, showing potent in vitro activity against various influenza strains, including H5N1 [3][10] - The seasonal influenza market represents a multi-billion dollar opportunity, driven by global health organizations and potential pandemic outbreaks [3] Ratutrelvir - Ratutrelvir is an investigational oral small molecule Mpro inhibitor for COVID-19, designed to be used without ritonavir, thus avoiding associated drug-drug interactions [4][10] - Preclinical and Phase 1 studies indicate that ratutrelvir maintains target blood plasma levels significantly above the EC50, potentially reducing the risk of clinical rebound and long COVID [4] Market Opportunities - The COVID-19 treatment market represents a potential multi-billion dollar opportunity, highlighting the ongoing need for improved therapies [4][10]